Ardelyx, Inc. - Common Stock (ARDX)

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability. Chief Financia

Ardelyx (ARDX) Q1 2026 Earnings Transcript

This biotech innovator in gastrointestinal and kidney therapies reported a notable insider sale amid routine portfolio adjustments.

Ardelyx is coming off a strong Q4 earnings report for fiscal year 2025. But how is the stock performing?

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.

The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share.

The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue.

Ardelyx (ARDX) Q3 2025 Earnings Call Transcript

The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock.

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Ardelyx (ARDX) stock surged 15% after Q3 2025 results, beating revenue estimates with strong growth from its drug IBSRELA and raising its full-year guidance.